Arrowhead Pharmaceuticals, Inc. · NASDAQ:ARWR
Arrowhead Pharmaceuticals — Technical Presentation (2022)
11 slides from Arrowhead Pharmaceuticals's technical presentation, 2022
Slide 1: ARO-APOC3 Decreases APOC3, Triglyceride, and Non-HDL-C in Severe Hypertriglyceridemia
#AHA22 ARO-APOC3, an Investigational RNAi Therapeutic, Decreases Serum Apolipoprotein C3, Triglyceride, and Non-HDL-C Concentrations While Increasing HDL-C in Patients With Severe Hypertriglyceridemia Christie M Ballantyne, MD Baylor College of Medicine on behalf of the SHASTA-2 Study Team
Slide 2: Financial Disclosure
Financial Disclosure Presenter CM Ballantyne reports grants and/or honoraria from Abbott Diagnostic, Akcea, Althera, Amarin, Amgen, Arrowhead, AstraZeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Ionis, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regener
Slide 3: Role of Apolipoprotein C3-Targeted Therapies in Severe Hypertriglyceridemia
Role of Apolipoprotein C3-Targeted Therapies in Severe Hypertriglyceridemia • Severe hypertriglyceridemia (SHTG) significantly increases risk of acute pancreatitis. • Currently, there are limited effective therapies to treat SHTG. • Apolipoprotein C3 (APOC3) regulates circulating levels of triglycer
Slide 4: SHASTA-2: Double-blind, Placebo-controlled, Dose Ranging Study of ARO-APOC3
SHASTA 2: An Ongoing Double-blind, Placebo-controlled, Dose Ranging Study of ARO-APOC3 in Subjects With SHTG Study Population: • SHTG history of TG > 500 mg/dL and ARO-APOC3 10 mg (N= 54) • fasting TG of 500 – 4,000 mg/dL during Placebo (N=18) screening period Randomization Screening/Diet Key Endpoi
Slide 5: Baseline Characteristics
Baseline Characteristics Pooled Placebo ARO-APOC3 (N=46) 10 mg (N=43) 25 mg (N=43) 50 mg (N=45) Mean (SD) age, years 56.3 (11.17) 53.9 (9.29) 56.0 (11.70) 54.8 (10.52) Female, n (%) 11 (24) 4 (9) 12 (28) 13 (29) White, n (%) 42 (91) 37 (86) 37 (86) 41 (91) Mean (SD) BMI, kg/m2 30.4 (3.8) 32.9 (5.1)
Slide 6: ARO-APOC3 Demonstrates Durable Decreases in Serum APOC3 and Triglycerides
ARO-APOC3 Demonstrates Durable Decreases in Serum APOC3 and Triglycerides at All Doses Studied APOC3 Triglycerides Mean (± SD) (APOC3, mg/dL) 60 2000 1500 50 Triglycerides mg/dL 1000 Median (Q1, Q3) 1000 40 800 30 11% 600 14% 20 73% 400 78% 10 82% 86% 200 0 87% 86% 0 0 2 4 6 8 10 12 14 16 0 2 4 6 8
Slide 7: ARO-APOC3 Decreases Serum Non-HDL-C and Increases HDL-C
ARO-APOC3 Decreases Serum Non-HDL-C and Increases HDL-C at All Doses Studied Non-HDL-C HDL-C Mean (± SD) (non-HDL-C, mg/dL) Mean (± SD) (HDL-C, mg/dL) 100 350 300 80 83% 250 3% 60 99% 200 37% 40 76% 150 45% 34% 20 4% 100 0 50 0 2 4 6 8 10 12 14 16 0 2 4 6 8 10 12 14 16 Study Week Study Week Placebo
Slide 8: Changes In LDL-C and non-HDL-C at Week 16
Changes In LDL-C and non-HDL-C at Week 16 Pooled Placebo ARO-APOC3 10 mg 25 mg 50 mg LDL-C (Ultracentrifugation) (mg/dL)* Baseline median (Q1,Q3) 54.0 (31.0, 88.0) 62.0 (29.0, 100.0) 62.5 (44.0, 92.0) 60.0 (30.0, 106.0) Median (Q1,Q3) at Week 16 72.5 (18.0, 90.0) 69.0 (38.0, 120.0) 64.5 (50.0, 126.0
Slide 9: Aggregated Summary of Adverse Events
Aggregated Summary of Adverse Events # of Subjects Reporting ≥ 1 Treatment Emergent Adverse Event (TEAE) N (%) 77/177(44%) • TEAEs reported to date reflect the TEAEs occurring in > 4 subjects N (%) underlying comorbidities and conditions of the population under study COVID-19 17 (10%) Headache 12 (7
Slide 10: Interim Analysis of SHASTA-2 Suggests Favorable Changes in Triglycerides and Non-HDL-C
Interim Analysis of SHASTA-2 Study Suggests Favorable Changes in Triglycerides and Non-HDL Cholesterol in Subjects With SHTG • Analysis was performed in SHASTA-2 once 50% of subjects reached their Week 12 visit • Interim results to date demonstrate that ARO-APOC3 durably decreases serum APOC3, TGs,
Slide 11: Thank You
THANK YOU LL fmcitsst iB Scientific #AHA22 Association. <E? Sessions
Arrowhead Pharmaceuticals — Technical Presentation (2022) on 6ix